Skip to main content

Securities & Capital Markets

Representative Initial Public Offerings (IPOs)

  • Hydrofarm Holdings Group, Inc. in its $199M initial public offering underwritten by JP Morgan and Stifel 
  • Galecto, Inc.: represented the underwriters (BofA Securities, SVB Leerink, Credit Suisse and and Kempen & Co.) in the $80M initial public offering
  • Praxis Precision Medicines, Inc.: represented the underwriters (Cowen, Evercore ISI, Piper Sandler, Wedbush PacGrow and Blackstone Capital Markets) in the $190M initial public offering
  • Inhibrx, Inc. in its $136.9M initial public offering underwritten by Jefferies LLC, Credit Suisse Securities and Evercore Group
  • Viela Bio, Inc. in its $172.6M initial public offering underwritten by Morgan Stanley, Goldman Sachs, Cowen and Guggenheim
  • Quanterix Corporation in its $64.1M initial public offering underwritten by JP Morgan, Leerink Partners, Cowen and Company, BTIG and Evercore ISI
  • Spero Therapeutics in its $77M initial public offering underwritten by BofA Merrill Lynch, Cowen and Company and Stifel
  • NuCana plc in its $114M initial public offering underwritten by Citigroup, Jefferies, Cowen and Company and William Blair
  • G1 Therapeutics, Inc. in its $105M initial public offering underwritten by J.P. Morgan Securities, Cowen and Company, Needham & Company and Wedbush Securities
  • WAVE Life Sciences in its $102M initial public offering underwritten by Jefferies, Leerink Partners, JMP Securities and Suntrust Robinson Humphrey
  • Brainsway Ltd.: represented the underwriters (Cantor, Raymond James, Oppenheimer & Co. and Ladenburg Thalmann) in the $35M initial public offering
  • Anchiano Therapeutics Ltd.: represented the underwriters (Oppenheimer & Co., Ladenburg Thalmann and LifeSci Capital) in the $30.5M initial public offering
  • Vaccinex Inc.: represented the underwriters (Oppenheimer, BTIG, LLC and Ladenburg Thalmann) in the $39.6M initial public offering
  • Neos Therapeutics, Inc.: represented the underwriters (UBS Investment Bank, BMO Capital Markets, RBC Capital Markets and JMP Securities) in the $82.8M initial public offering
  • Dicerna Pharmaceuticals, Inc.: represented the underwriters (Jefferies, Leerink, Stifel and Baird) in the $103M initial public offering

Representative Follow-on Public Offerings – Issuer-Side Representation

  • Wave Life Sciences in its $100M public offering underwritten by Jefferies, SVB Leerink, Mizuho Securities, Truist Securities and H.C. Wainwright and Co.
  • NuCana plc in its $80M public offering underwritten by Citigroup, Jefferies, Cowen and Company, William Blair and Truist Securities
  • Spero Therapeutics in its $80M public offering underwritten by Cowen and Company, Evercore and Cantor Fitzgerald
  • Intra-Cellular Therapies in its $380M public offering underwritten by J.P. Morgan, Goldman Sachs, SVB Leerink, Evercore, Cantor Fitzgerald and Canaccord Genuity
  • Quanterix Corporation in its $91M public offering underwritten by SVB Leerink, Cowen and Company and Canaccord Genuity
  • Viela Bio, Inc. in its $169.2M public offering underwritten by Morgan Stanley, Goldman Sachs, Cowen and Guggenheim
  • Evofem Biosciences Inc. in its $100M public offering underwritten by Morgan Stanley, Piper Sandler, Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC
  • Intra-Cellular Therapies in its $295M public offering underwritten by J.P. Morgan, Leerink, Evercore, Cantor Fitzgerald, Canaccord Genuity and JMP
  • Molecular Templates, Inc. in its $58M public offering underwritten by Cowen, Barclays and Stifel
  • ImmunoGen, Inc. in its $104M public offering underwritten by Jefferies, Cowen and William Blair
  • Fulgent Genetics in its $27.5M public offering underwritten by Piper Jaffray
  • Quanterix Corporation in its $69M public offering underwritten by J.P. Morgan Securities, SVB Leerink and Canaccord Genuity 
  • Albireo Pharma, Inc. in its $40M public offering underwritten by Jefferies
  • X4 Pharmaceuticals, Inc. in its $85.8M public offering underwritten by Cowen, Stifel and Canaccord Genuity

Representative Follow-on Public Offerings – Underwriters’ Representation

  • $492M public offering of Acceleron Pharma Inc. underwritten by JP Morgan Securities, SVB Leerink, Cowen and Company, Barclays, Credit Suisse and Piper Sandler
  • $152M public offering of Mersana Therapeutics underwritten by Cowen and Company, SVB Leerink, Wedbush PacGrow, Baird and H.C. Wainwright & Co.
  • $50M public offering of Trevena, Inc. underwritten by Guggenheim Securities
  • $50M public offering of Soleno Therapeutics, Inc. underwritten by Guggenheim Securities, Oppenheimer & Co. and Maxim Group LLC
  • $140M public offering of Geron Corporation underwritten by Stifel and MTS Health Partners
  • $75M public offering of Axovant Gene Therapies underwritten by SVB Leerink
  • $32M public offering of Misonix, Inc. underwritten by Canaccord Genuity, BTIG and Craig-Hallum Capital Group
  • $225M public offering of uniQure NV underwritten by Goldman Sachs, SVB Leerink, Stifel, Cantor, SunTrust Robinson Humphrey and H.C. Wainwright & Co.
  • $63M public offering of Exicure underwritten by Guggenheim Securities
  • $103M public offering of ArQule, Inc. underwritten by SVB Leerink, RBC Capital Markets, Oppenheimer & Co., Needham, Roth, B. Riley FBR and JonesTrading
  • $97M public offering of Mersana Therapeutics underwritten by SVB Leerink and Wedbush
  • $130.6M public offering of Adverum Biotechnologies, Inc. underwritten by SVB Leerink LLC, Goldman Sachs & Co. LLC, Cowen and LifeSci Capital, LLC
  • $345M public offering of American Depositary Shares of GW Pharmaceuticals plc underwritten by Goldman Sachs, Morgan Stanley, J.P. Morgan and Cowen and Company
  • $115M public offering of Dicerna Pharmaceuticals, Inc. underwritten by Stifel Nicolaus, Citigroup, H.C. Wainwright & Co. and SunTrust Robinson Humphrey
Case Study
After a lender abandoned our client’s financing transaction over concerns related to COVID-19, Mintz negotiated a convertible note financing with another investor — providing the client with up to $25M to pursue commercialization of its lead product.
Case Study
Mintz transactional and health regulatory professionals represented clinical-stage oncology company G1 Therapeutics in its $108.6 million initial public offering (IPO).
Case Study
Mintz advised Oberon Fuels, a developer of an ultra-low-carbon fuel known as renewable dimethyl ether (rDME), on a strategic collaboration with propane fuel distributor SHV Energy. The agreement will help Oberon scale up its pilot facility to produce the first rDME fuel in the United States.
Case Study
Mintz represented Spero Therapeutics, a clinical-stage biopharmaceutical company developing treatments for drug-resistant bacterial infections, in a September 2020 underwritten public offering that netted $80 million in gross proceeds before the deduction of underwriting discounts and commissions.
Case Study
In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.
Case Study
After helping Spero raise over $200 million, Mintz represented the biopharmaceutical company in its collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis (Mtb).
Case Study
Mintz helped women’s reproductive health care company Daré Bioscience Operations, Inc. become a wholly owned subsidiary of Cerulean and a publicly traded company named Daré Bioscience, Inc. The innovative deal utilized a variation of a reverse merger into a publicly traded fallen-angel.
Case Study
Mintz steered precision health company Quanterix Corporation through a $73.7 million initial public offering (IPO). The firm’s Securities & Capital Markets Practice advised Quanterix on the Securities and Exchange Commission review process as well as pricing and timing of the offering.
Case Study
Mintz’s work for synthetic biotic company Synlogic Inc. has included raising over $100 million in three VC financing rounds. Mintz attorneys also helped Synlogic form a multiyear global R&D collaboration with AbbVie and raise more than $40 million in an IPO via a reverse merger with Mirna Therapeutics.